Tech Center 1600 • Art Units: 1615 1617 1621 1627 1628 1629
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18250811 | DIRECT DELIVERY OF VITAMINS TO REBALANCE GUT MICROBIOME AFTER EXPOSURE TO ANTIBIOTICS | Non-Final OA | DSM IP ASSETS B.V. |
| 18281037 | COMPOSITION FOR CONTROLLING FLYING PEST INSECTS | Non-Final OA | Kao Corporation |
| 18461562 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 17637005 | STABLE CREATINE BEVERAGES | Final Rejection | The Coca-Cola Company |
| 18574883 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING KIDNEY INJURY, AND AUTOPHAGY ACTIVATOR | Non-Final OA | KYOTO UNIVERSITY |
| 18102296 | ADMINISTRATION OF MODULATORS OF 5-HT AND / OR AMPA RECEPTORS FOR TREATING NEUROLOGICAL CONDITIONS | Final Rejection | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY |
| 17929895 | Compositions and Methods for Treating CNS Disorders | Final Rejection | Lipocine Inc. |
| 18433069 | Methods of Treating Testosterone Deficiency | Non-Final OA | Tolmar, Inc. |
| 18451557 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | Non-Final OA | Tolmar, Inc. |
| 18230749 | PHARMACEUTICAL PREPARATION FOR ASSISTING IN PROMOTING SLEEP AND PREPARATION METHOD THEREOF | Non-Final OA | Changde Jizhi Biological Technology Co., Ltd |
| 17086409 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Non-Final OA | AQUESTIVE THERAPEUTICS, INC. |
| 18555505 | NITROPHENYL-ACRYLAMIDES AND USES THEREOF | Non-Final OA | Rhode Island Hospital |
| 18563876 | FAST DISSOLVING ORAL FILM PREPARATION COMPRISING RIVAROXABAN | Non-Final OA | Shilpa Medicare Limited |
| 18520464 | METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER | Final Rejection | NAPO PHARMACEUTICALS, INC. |
| 18515702 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | Non-Final OA | ReveraGen BioPharma, Inc. |
| 18254623 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. |
| 17993020 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | Non-Final OA | Sage Therapeutics, Inc. |
| 18264143 | COMPOSITIONS AND METHODS FOR TREATMENT OF HIDRADENITIS SUPPURATIVA | Non-Final OA | SUZHOU KINTOR PHARMACEUTICALS, INC. |
| 18077212 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES | Non-Final OA | TherapeuticsMD, Inc. |
| 18368514 | POLYSUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Non-Final OA | Hubei Biopesticide Engineering Research Centre |
| 18462162 | EMULSIONS FOR LOCAL ANESTHETICS | Non-Final OA | CALI BIOSCIENCES US, LLC |
| 18450638 | COMBINATION OF RAF INHIBITOR AND MEK INHIBITOR | Non-Final OA | DAY ONE BIOPHARMACEUTICALS, INC. |
| 18268128 | A COMPOSITION FOR USE IN THE TREATMENT OF INFERTILITY | Final Rejection | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY |
| 18267395 | SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE | Non-Final OA | Galapagos NV |
| 18037007 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PRETERM LABOR | Non-Final OA | XOMA (US) LLC |
| 18252351 | OMEGA-3 POLYUNSATURATED FATTY ACIDS FOR TREATING / PREVENTING MALE INFERTILITY IN PREPUBERTAL CANDIDATES FOR GONADOTOXIC THERAPIES | Non-Final OA | UNIVERSITA' DEGLI STUDI DI PERUGIA |
| 18031748 | USE OF COMBINED ORAL CONTRACEPTIVES CONTAINING NOMEGESTROL ACETATE AND ESTRADIOL | Final Rejection | THERAMEX HQ UK LIMITED |
| 18248626 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | Non-Final OA | GOODCAP PHARMACEUTICALS LTD. |
| 17359726 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE | Final Rejection | IMBRIA PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy